2015 half-year activity
(Unaudited data)
Cumulative activity as of the end of june 2015
| thousands of euros | 2014 | 2015 | Variation at current exchange rates | Variation at constant exchange rates |
| France | 157,018 | 166,448 | + 6.0% | + 6.0% |
| Europe (excluding France) | 73,537 | 70,600 | - 4.0% | - 2.6% |
| North America | 23,287 | 30,087 | + 29.2% | + 7.7% |
| Other countries | 7,774 | 8,438 | + 8.5% | + 9.7% |
| Group total | 261,616 | 275,573 | + 5.3% | + 3.9% |
| thousands of euros | 2014 | 2015 | Variation at current exchange rates | Variation at constant exchange rates |
| Non-proprietary Homeopathic Medicines | 150,991 | 153,545 | + 1.7% | + 0.7% |
| OTC Specialties | 110,254 | 121,910 | + 10.6% | + 8.4% |
| Other | 371 | 118 | - 68.2% | - 43.9% |
| Group total | 261,616 | 275,573 | + 5.3% | + 3.9% |
Activity in the quarter (variation at current rate)
| thousands of euros | 1st Quarter | 2nd Quarter | ||||
| 2014 | 2015 | Var. 15/14 | 2014 | 2015 | Var. 15/14 | |
| France | 82,749 | 89,584 | +8.3% | 74,269 | 76,864 | +3.5% |
| Europe (excluding France) | 39,967 | 40,657 | +1.7% | 33,570 | 29,943 | -10.8% |
| North America | 12,662 | 17,193 | +35.8% | 10,625 | 12,894 | +21.4% |
| Other countries | 4,831 | 4,622 | -4.3% | 2,943 | 3,816 | +29.7% |
| Group total | 140,209 | 152,056 | +8.4% | 121,407 | 123,517 | +1.7% |
| thousands of euros | 1st Quarter | 2nd Quarter | ||||
| 2014 | 2015 | Var. 15/14 | 2014 | 2015 | Var. 15/14 | |
| Non-proprietary Homeopathic Medicines | 77,919 | 79,191 | +1.6% | 73,072 | 74,354 | +1.8% |
| OTC Specialties | 62,196 | 72,880 | +17.2% | 48,058 | 49,030 | +2.0% |
| Other | 94 | -15 | - | 277 | 133 | -52.0% |
| Group total | 140,209 | 152,056 | +8.4% | 121,407 | 123,517 | +1.7% |
Highlights of the second quarter 2015
Sales in the second quarter of 2015 rose by 1.7% compared to the second quarter of 2014: business activity increased in France and the US and decreased, especially, in Russia, Spain and Poland.
Profitability in the first half of 2015 should rise compared to 2014.
BOIRON will continue its involvement in the development of homeopathy with confidence and ambition. Taking into account the geopolitical risks, especially in Russia, the BOIRON group remains cautious in its outlook for 2015.
Our next update:
September 3, 2015: at market close, publication of 2015 half-year results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : [email protected]
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at: www.boironfinance.com
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-40724-BOI-170715-CA-T2-GB.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Quelle: Actusnews
